Developmental Dysphasia FamilialSymptoms, Doctors, Treatments, Advances & More
Developmental Dysphasia Familial Overview
Learn About Developmental Dysphasia Familial
- Developmental dysphasia familial
- Developmental language disorder
- Specific language impairment
Mayo Clinic-Rochester
David Knopman is a Neurologist practicing medicine in Virginia Beach, Virginia. Dr. Knopman is rated as an Elite provider by MediFind in the treatment of Developmental Dysphasia Familial. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Dementia, Alzheimer's Disease, Lewy Body Dementia (LBD), and Frontotemporal Dementia. Dr. Knopman is currently accepting new patients.
Mohamad El Haj practices practicing medicine in Nantes, France. Mr. El Haj is rated as an Elite expert by MediFind in the treatment of Developmental Dysphasia Familial. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Memory Loss, Developmental Dysphasia Familial, Alzheimer's Disease, and Dementia.
Murfreesboro Medical Clinic (MMC)
Robert Humphrey is a Pediatrics provider practicing medicine in Murfreesboro, Tennessee. Dr. Humphrey is rated as an Experienced provider by MediFind in the treatment of Developmental Dysphasia Familial. His clinical expertise encompasses Developmental Dysphasia Familial, Sunken Fontanelles, Viral Gastroenteritis, and Delayed Growth. Dr. Humphrey is board certified in Board Certified American Board Of Pediatrics. Dr. Humphrey is currently accepting new patients.
Summary: While many have strongly suggested that transcranial direct current stimulation (tDCS) may represent a beneficial intervention for patients with primary progressive aphasia (PPA), this promising technology has not yet been applied widely in clinical settings. This treatment gap is underscored by the absence of any neurally-focused standard-of-care treatments to mitigate the devastating impact of a...
Summary: The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and Aβ analysis in cerebrospinal fluid samples. The BioFINDER 1 study has resulted in more than ...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center
